CA-LAMBDATEST
2.2.2023 14:01:47 CET | Business Wire | Press release
LambdaTest, the leading continuous quality testing cloud platform, has announced the launch of digital experience testing cloud for enterprises. The offering will enable enterprises to accelerate their digital transformation by providing a best-in-class, 360-degree test execution and orchestration platform coupled with insightful test analytics and customizable deployment options.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230202005474/en/
LambdaTest’s digital experience testing cloud will enable enterprises to test for omnichannel experiences on custom-designed, robust, and scalable infrastructure (Graphic: Business Wire)
According to Forrester’s Best Practice Report titled ‘Optimize Your Digital Experience To Compete For Customers’, “No matter how embedded your brand is in customers’ lives today, if you stop meeting their expectations, it’s easy for them to switch to a competitor tomorrow. As the ratio of digital to nondigital customer interactions continues to increase, both digital customer experiences and the data that firms collect about them will evolve in ways that will challenge and reward insights-driven, customer-led organizations.”
Enterprises across the globe are striving to cater to the growing needs of digital-native customers. This translates to developers constantly working to provide a high-quality experience to customers while applications are undergoing continuous change. Such a high-pressure scenario demands quick developer feedback to enable faster release velocity. However, test execution ends up being the roadblock because enterprises depend on legacy cloud-based test execution platforms that are slow, brittle, and flaky or on in-house infrastructure that is hard to maintain, grow, and scale.
With LambdaTest’s digital experience testing cloud, enterprises can pick and choose across cross-browser testing (live and automated), real devices testing (live and automated), visual regression testing, and OTT app testing, thereby ensuring coverage across the entire gamut of omnichannel options. Moreover, the smart workflows like auto-grouping, auto-retry, and fail-fast techniques, offered by the testing cloud will do the heavy lifting, allowing testers/developers to concentrate on test creation.
Enterprises can decide their mode of deployment–multi-tenant, dedicated cloud, or on-premise. To top it off, enterprises will have access to centralized test analytics and observability that will unify all test execution data and enable informed decision-making.
The digital experience testing cloud will seamlessly fit into the CI/CD pipeline with 120+ integrations across categories like communication, bug tracking, test management, test authoring, and automation. Also, LambdaTest is SOC 2 Type II, ISO 27001, ISO 27017, and ISO 27701 standard certified, and GDPR, CCPA, and HIPAA-ready compliant.
“According to Gartner’s Market Guide for Digital Experience Monitoring, ‘By 2026, at least 60% of I&O leaders will use Digital Experience Monitoring to measure application, services and endpoint performance from the user’s viewpoint, up from less than 20% in 2021’. This clearly points to how central digital experience has become for enterprises. The LambdaTest digital experience testing cloud platform provides a comprehensive solution for modern enterprises to evolve their testing experience and thereby enhance the usability and performance of web and mobile applications to help deliver a best-in-class digital experience to their digital-native customers,” said Asad Khan, Co-Founder & CEO, LambdaTest.
“What we promise enterprises is straightforward and simple—our hyper-scalable digital experience testing cloud will be the digital highway for test execution and will reduce developer interrupts/friction, ensure faster feedback, and positively impact release velocity and go-to-market speed. This is bringing test execution to the digital era!” he added.
Recently, Satya Nadella, Chairman & CEO of Microsoft, delivered the keynote address at the Microsoft Future Ready Technology Summit 2023, Bengaluru, where he said that “LambdaTest is doing for test automation what Kubernetes did for container orchestration - creating that next level of efficiency around test automation so that people can actually focus on testing versus test orchestration.”
To know more, visit: https://www.lambdatest.com/enterprise
About LambdaTest
LambdaTest is a leading digital experience testing cloud that helps developers and testers ship code faster. Over 10,000+ enterprise customers and 2+ million users across 130+ countries rely on LambdaTest for their testing needs.
The LambdaTest platform provides secure, scalable, and insightful test orchestration for customers at different points in their DevOps (CI/CD) lifecycle:
- Browser & App Testing Cloud allows users to run both manual and automated tests of web and mobile apps across 3000+ different browsers, real devices, and operating system environments.
- HyperExecute helps customers run and orchestrate test grids in the cloud for any framework and programming language at blazing-fast speeds to cut down on quality test time, helping developers build software faster.
For more information, please visit: https://lambdatest.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230202005474/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom